tetano
Editor, Senior Moderator
Vaccine
. 2024 Jan 27:S0264-410X(24)00099-9.
doi: 10.1016/j.vaccine.2024.01.074. Online ahead of print. Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells
Xin-Yue Yang[SUP] 1 [/SUP], Ting Liu[SUP] 2 [/SUP], Si-Cong Jiang[SUP] 3 [/SUP], Zhong-Wei Zhang[SUP] 1 [/SUP], Yu-Fan Fu[SUP] 1 [/SUP], Zi-Lin Li[SUP] 4 [/SUP], Jing Hu[SUP] 5 [/SUP], Shu Yuan[SUP] 6 [/SUP]
Affiliations
Coronavirus Disease 2019 (COVID-19) vaccines protect the public and limit viral spread. However, inactivated viral vaccines use the whole virus particle, which contains many non-capsid proteins that may cause adverse immune responses. A report has found that the ADP-ribose-binding domains of SARS-CoV-2 non-structural protein 3 (NSP3) and human poly(ADP-ribose) polymerase family member 14 (PARP14) share a significant degree of homology. Here, we further show that antibodies against 2019 novel SARS-like coronavirus (SARS-CoV-2) NSP3 can bind human PARP14 protein. However, when G159R + G162R mutations were introduced into NSP3, the antibody titer against human PARP14 decreased 14-fold. Antibodies against SARS-CoV-2 NSP3 can cross-react with human skeletal muscle cells and astrocytes, but not human embryonic kidney 293T cells. However, when G159R + G162R mutations were introduced into NSP3, the cross-reaction was largely inhibited. The results imply that COVID-19 patients with high antibody titers against NSP3 may have high risks of muscular and/or neurological complications. And the possible strategies to improve the safety of inactivated viral vaccines are also discussed.
Keywords: Antibody cross-reaction; Astrocytes; Human PARP14; Human skeletal muscle cells; SARS-CoV-2 NSP3.
. 2024 Jan 27:S0264-410X(24)00099-9.
doi: 10.1016/j.vaccine.2024.01.074. Online ahead of print. Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells
Xin-Yue Yang[SUP] 1 [/SUP], Ting Liu[SUP] 2 [/SUP], Si-Cong Jiang[SUP] 3 [/SUP], Zhong-Wei Zhang[SUP] 1 [/SUP], Yu-Fan Fu[SUP] 1 [/SUP], Zi-Lin Li[SUP] 4 [/SUP], Jing Hu[SUP] 5 [/SUP], Shu Yuan[SUP] 6 [/SUP]
Affiliations
- PMID: 38281898
- DOI: 10.1016/j.vaccine.2024.01.074
Coronavirus Disease 2019 (COVID-19) vaccines protect the public and limit viral spread. However, inactivated viral vaccines use the whole virus particle, which contains many non-capsid proteins that may cause adverse immune responses. A report has found that the ADP-ribose-binding domains of SARS-CoV-2 non-structural protein 3 (NSP3) and human poly(ADP-ribose) polymerase family member 14 (PARP14) share a significant degree of homology. Here, we further show that antibodies against 2019 novel SARS-like coronavirus (SARS-CoV-2) NSP3 can bind human PARP14 protein. However, when G159R + G162R mutations were introduced into NSP3, the antibody titer against human PARP14 decreased 14-fold. Antibodies against SARS-CoV-2 NSP3 can cross-react with human skeletal muscle cells and astrocytes, but not human embryonic kidney 293T cells. However, when G159R + G162R mutations were introduced into NSP3, the cross-reaction was largely inhibited. The results imply that COVID-19 patients with high antibody titers against NSP3 may have high risks of muscular and/or neurological complications. And the possible strategies to improve the safety of inactivated viral vaccines are also discussed.
Keywords: Antibody cross-reaction; Astrocytes; Human PARP14; Human skeletal muscle cells; SARS-CoV-2 NSP3.